Author:
Luboldt Wolfgang,Zöphel Klaus,Wunderlich Gerd,Abramyuk Andrij,Luboldt Hans-Joachim,Kotzerke Joerg
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Radiology Nuclear Medicine and imaging,Oncology
Reference34 articles.
1. Heidenreich A, Ohlmann CH (2005) Treatment options for hormone-refractory prostate cancer. Urologe A 44(11):1303–4, 1306–14
2. Schmid HP, Gregorin J, Altwein JE (2008) Growth hormone inhibitors in prostate cancer: a systematic analysis. Urol Int 81(1):17–22
3. Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP (1999) Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 40(5):762–767
4. Cremonesi M, Ferrari M, Zoboli S et al (1999) Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med 26(8):877–886
5. Chinol M, Bodei L, Cremonesi M, Paganelli G (2002) Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 32(2):141–147
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献